(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 23.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Prothena Public Co's revenue in 2026 is $54,530,000.On average, 8 Wall Street analysts forecast PRTA's revenue for 2026 to be $4,434,385,140, with the lowest PRTA revenue forecast at $2,570,852,984, and the highest PRTA revenue forecast at $5,718,425,534. On average, 8 Wall Street analysts forecast PRTA's revenue for 2027 to be $1,382,402,036, with the lowest PRTA revenue forecast at $0, and the highest PRTA revenue forecast at $5,390,382,270.
In 2028, PRTA is forecast to generate $7,057,293,816 in revenue, with the lowest revenue forecast at $5,131,643,921 and the highest revenue forecast at $8,209,808,882.